A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

NCT06719011 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how a medication called NNC0174-1213 works in adults who are overweight or have obesity, focusing on the side effects reported during the study.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 177 people Planned (estimated).

Who can join Ages 18–55 · male only

Timeline Started 2024-12 · est. completion 2026-05

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06719011 ↗

Description as written by the study sponsor.

This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.

Treatments tested

NNC0174-1213 A Drug

Participants will be randomized to receive NNC0174-1213 A administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Cagrilintide B Drug

Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Placebo A (NNC0174 1213 A) Drug

Participants will be randomized to receive Placebo administered as subcutaneous (s.c. under the skin) injection. Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.

Main thing measured	Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06719011 ↗